Koers Harpoon Therapeutics, Inc.
Aandelen
HARP
US41358P2056
Biotechnologie & Medisch Onderzoek
Vertraagde tijd
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
23,01 USD | +0,09% | 0,00% | +102,37% |
11/03 | Merck rondt overname van Harpoon Therapeutics af | MT |
11/03 | Merck Sharp & Dohme LLC heeft de overname afgerond van Harpoon Therapeutics, Inc. (NasdaqCM:HARP). | CI |
Recentste transcriptie over Harpoon Therapeutics, Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Julia Eastland
CEO | Chief Executive Officer | 59 | 11-10-18 |
Frank Lanza
DFI | Director of Finance/CFO | 62 | 01-04-19 |
Chatan Charan
CTO | Chief Tech/Sci/R&D Officer | - | 01-11-22 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Julia Eastland
CEO | Chief Executive Officer | 59 | 11-10-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+2,56% | 108 mld. | |
+10,02% | 104 mld. | |
+7,57% | 23,66 mld. | |
-11,91% | 22,1 mld. | |
-3,29% | 19,71 mld. | |
-35,98% | 18,2 mld. | |
-14,02% | 16,19 mld. | |
+4,61% | 13,72 mld. | |
+35,05% | 12,22 mld. |